Login to Your Account



Ganymed Gets €65M for Cancer-Specific Antibodies

By Cormac Sheridan


Wednesday, November 19, 2008

No Abstract

 

BioWorld International Correspondent

Ganymed Pharmaceuticals AG landed one of Europe's landmark private equity deals of 2008, a €65 million (US$82.2 million) fourth financing round that will fund preclinical and early clinical development of a broad pipeline of its cancer-specific antibody therapies in multiple oncology indications.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription